Merck's $10.8B Prometheus buyout can proceed after antitrust review

Nicole DeFeudis

Editor

The government’s waiting period for Merck’s $10.8 billion Prometheus Biosciences buyout expired on Monday, meaning the companies can proceed to close the deal, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's $10.8B Prometheus buyout can proceed after antitrust review

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Updated: Biogen makes cuts across its research unit, shifting focus to ‘external opportunities’

Anthos' detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer's failed?

Teva’s MS drug and generics to add black box warning for anaphylaxis

China's biotech boom is threatening US drugmakers' dominance

Chinese startup begins first trial of in vivo CRISPR therapy for blood disease

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Mer­ck­'s $10.8B Prometheus buy­out can pro­ceed af­ter an­titrust re­view

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Merck's $10.8B Prometheus buyout can proceed after antitrust review